Xenon Pharmaceuticals Inc. said it will present data from its Phase 3 X-TOLE2 study of azetukalner at the 16th European Epilepsy Congress in Athens, Greece, from September 5 to 9.
The company will host an exhibition booth at stand #9 in the Exhibit Hall from September 5 to 8 and deliver six presentations. An oral presentation of the X-TOLE2 results is scheduled for Monday, September 7, during the Platform Session on Drug Therapy and Clinical Trials from 12:15 to 1:45 PM EEST. A poster presentation on the drug’s mechanism will occur on Sunday, September 6, from 2:00 to 3:00 PM EEST.
The X-TOLE2 study is a randomized, double-blind, placebo-controlled Phase 3 trial evaluating azetukalner as adjunctive therapy for focal onset seizures. The trial enrolled 380 participants, randomized to receive either azetukalner at 25 mg, 15 mg, or placebo. Participants had a median of five prior antiseizure medications and a baseline seizure frequency of 12.75 per month.
Of the 380 participants, 332 completed the double-blind period, and 322 entered the open-label extension study. The extension includes patients with at least 48 months of follow-up data. Azetukalner, a potassium channel opener, is also being studied for major depressive disorder and bipolar depression.
Focal epilepsy affects roughly 3 million adults in the United States, with up to half experiencing uncontrolled seizures despite existing treatments.
